Clinical Trials Logo

Clinical Trial Summary

Acute Myeloid Leukemia (AML) is currently treated with chemotherapy by combining several drugs with different ways of inhibiting the cell growth. In this trial, standard chemotherapeutics that have proven their effectiveness for years, Ara-C and Idarubicin, will be combined with a new drug called Selinexor. Selinexor inhibits the growth of cancer cells by keeping certain proteins in the nucleus which control the cell growth.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02249091
Study type Interventional
Source GSO Global Clinical Research BV
Contact
Status Completed
Phase Phase 2
Start date September 2014
Completion date July 31, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05951855 - Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients Phase 2